Keenova Therapeutics Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Keenova Therapeutics Plc in the first quarter 2026?
Keenova Therapeutics Plc recorded a cumulative net loss of $-573 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -26.04%.

Within the Major Pharmaceutical Preparations industry 77 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2237, from total ROE ranking in the fourth quarter 2025 at 2639.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 26 2025) III. Quarter	(Mar 28 2025) I. Quarter	(Sep 27 2024) III. Quarter
Y / Y Equity Change	90.45 %	96.97 %	188.61 %	40.49 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-573	-486	-388	-163	1,870
Return On Equity (TTM)	-26.04 %	-24.68 %	-22.65 %	-13.55 %	172.76 %
MNK's Total Ranking	# 2237	# 2639	# 2659	# 2566	#
Equity (TTM) in Millions	1,958	2,065	3,151	1,630	1,028
Seq. Equity Change	-5.17 %	-34.47 %	93.33 %	58.51 %	-1.93 %
Seq. Net Income Change	-	-	-	-	-

Back to MNK Management Effectiveness >> MNK's 5 Years Annual ROE >> Compare MNK ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 78
Sector	# 238
Overall	# 2237

Return On Equity Statistics
High	Average	Low
172.76 %	-66.49 %	-453.63 %
(Sep 27 2024)		(Sep 29 2023)

MNK Annual Return On Equity	(Dec 31 2025) 2025	(Dec 29 2023) 2023	(Dec 30 2022) 2022
Total Equity in Millions	2,065	1,160	1,614	0	0
Y / Y Equity Change	78 %	-28.1 %	-	-	-
Net Income in Millions	-490	-717	-717	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-23.7 %	-61.83 %	-44.46 %	-	-

Back to MNK Management Effectiveness >> MNK's 5 Years Annual ROE >> Compare MNK ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MNK's' Return on Equity at Yahoo Finance
MNK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MNK's Competitors
Subscribers only: Roe for Keenova Therapeutics Plc's Suppliers
Subscribers only: Return On Equity for MNK's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.